Karl Erik Andersson

Summary

Affiliation: Lund University Hospital
Country: Sweden

Publications

  1. ncbi Pharmacologic perspective on the physiology of the lower urinary tract
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Urology 60:13-20; discussion 20-1. 2002
  2. ncbi New pharmacologic targets for the treatment of the overactive bladder: an update
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Urology 63:32-41. 2004
  3. ncbi Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Nat Clin Pract Urol 4:368-78. 2007
  4. ncbi Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
    K E Andersson
    Department of Clinical Pharmacology, Institute for Laboratory Medicine, Lund University Hospital, S 221 85 Lund, Sweden
    Eur Urol 43:1-5. 2003
  5. ncbi Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Neurourol Urodyn 30:292-301. 2011
  6. ncbi Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, S 221 85 Lund, Sweden
    Pharmacol Rev 56:581-631. 2004
  7. ncbi CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Drugs 63:2595-611. 2003
  8. ncbi Storage and voiding symptoms: pathophysiologic aspects
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Urology 62:3-10. 2003
  9. ncbi Antimuscarinics for treatment of overactive bladder
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Lancet Neurol 3:46-53. 2004
  10. ncbi [Changes in muscarinic receptors of the aging bladder]
    K E Andersson
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden
    Urologe A 43:552-6. 2004

Collaborators

Detail Information

Publications84

  1. ncbi Pharmacologic perspective on the physiology of the lower urinary tract
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Urology 60:13-20; discussion 20-1. 2002
    ..If this component of activation is responsible not only for part of the bladder contractions, but also for the symptoms of the overactive bladder, it should be considered an important target for therapeutic interventions...
  2. ncbi New pharmacologic targets for the treatment of the overactive bladder: an update
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Urology 63:32-41. 2004
    ..However, development of other agents that block afferent or efferent nerve impulses in the bladder through activity at vanilloid, purinergic, or opioid-like receptor sites may result in clinically useful drugs...
  3. ncbi Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Nat Clin Pract Urol 4:368-78. 2007
    ....
  4. ncbi Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
    K E Andersson
    Department of Clinical Pharmacology, Institute for Laboratory Medicine, Lund University Hospital, S 221 85 Lund, Sweden
    Eur Urol 43:1-5. 2003
    ..It is suggested that this release, which is increased by stretching the muscle and in the aging bladder, contributes to detrusor overactivity and OAB by eventually increasing bladder afferent activity during storage...
  5. ncbi Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Neurourol Urodyn 30:292-301. 2011
    ..This manuscript reviews the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition...
  6. ncbi Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, S 221 85 Lund, Sweden
    Pharmacol Rev 56:581-631. 2004
    ..New targets for control of micturition are being defined, but further research is needed to advance the pharmacological treatment of micturition disorders...
  7. ncbi CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Drugs 63:2595-611. 2003
    ..However, considering the limited predictability of existing animal models for efficacy in humans, positive proof of concept studies in humans are mandatory. Such studies are scarce and further investigations are needed...
  8. ncbi Storage and voiding symptoms: pathophysiologic aspects
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Urology 62:3-10. 2003
    ..LUTS can be caused by many, often overlapping, pathophysiologic mechanisms, which may contribute to individual variation in response to treatment...
  9. ncbi Antimuscarinics for treatment of overactive bladder
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Lancet Neurol 3:46-53. 2004
    ..Further clinical trials with improvement in quality of life as the primary endpoint are needed and may give a fair reflection of the clinical value of antimuscarinic drugs...
  10. ncbi [Changes in muscarinic receptors of the aging bladder]
    K E Andersson
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden
    Urologe A 43:552-6. 2004
    ..However, the clinical consequence of this is unclear, since no major age-dependent changes in the efficacy of antimuscarinic agents in the treatment of OAB have been demonstrated...
  11. ncbi Mechanisms of Disease: central nervous system involvement in overactive bladder syndrome
    Karl Erik Andersson
    University of Lund, Sweden
    Nat Clin Pract Urol 1:103-8. 2004
    ..This short overview focuses on the afferent pathways and on how the transmitter systems that control micturition can be perturbed by disease to give rise to DO/OABS...
  12. ncbi Detrusor myocyte activity and afferent signaling
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Neurourol Urodyn 29:97-106. 2010
    ....
  13. ncbi The pharmacological treatment of nocturia
    K-E Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Sweden
    BJU Int 90:25-7. 2002
  14. ncbi Neurophysiology/pharmacology of erection
    K E Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Int J Impot Res 13:S8-S17. 2001
    ..Further research in this area may be rewarding...
  15. ncbi Oxybutynin and the overactive bladder
    K E Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Sweden
    World J Urol 19:319-23. 2001
    ..A controlled-release preparation has recently been introduced. Oxybutynin has a well-documented efficacy in the treatment of detrusor overactivity, and is a drug of first choice in patients with this disorder...
  16. ncbi The basis for drug treatment of the overactive bladder
    K E Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Sweden
    World J Urol 19:294-8. 2001
    ..Several CNS transmitters can modulate voiding, but few drugs with a defined CNS site of action have been demonstrated to be clinically useful. Traditionally, drugs for treatment o..
  17. ncbi Pharmacology of penile erection
    K E Andersson
    Department of Clinical Pharmacology, Lund University Hospital, S 22185 Lund, Sweden
    Pharmacol Rev 53:417-50. 2001
    ..Dopamine receptors in central nervous centers participating in the initiation of erection have been targeted for the treatment of ED. Apomorphine, administered sublingually, is the first of such drugs...
  18. ncbi Penile erectile function: recommendations for future research
    K E Andersson
    Department of Clinical Pharmacology, University of Lund, Lund, Sweden
    Int J Impot Res 12:S163-7. 2000
    ..Intracavernosal somatic gene therapy is promising, and new molecular targets for drug treatments should be identified and explored. International Journal of Impotence Research (2000) 12, Suppl 4, S163-S167...
  19. ncbi Neurotransmitters: central and peripheral mechanisms
    K E Andersson
    Department of Clinical Pharmacology, University of Lund, Lund, Sweden
    Int J Impot Res 12:S26-33. 2000
    ..The role of other mediators, released from nerves or endothelium has not been definitely established. International Journal of Impotence Research (2000) 12, Suppl 4, S26-S33...
  20. ncbi Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists
    Karl Erik Andersson
    Department of Clinical Pharmacology, Institute for Laboratory Medicine, Lund University Hospital, Sweden
    World J Urol 19:390-6. 2002
    ..Despite the above uncertainties, there seems to be a consensus that clinically available alpha1-AR antagonists provide a safe, effective and generally well-tolerated therapy for patients with LUTS...
  21. ncbi Future drugs for the treatment of benign prostatic hyperplasia
    Karl Erik Andersson
    Department of Clinical Pharmacology, Institute for Laboratory Medicine, Lund University Hospital, Sweden
    World J Urol 19:436-42. 2002
    ..For new treatments of LUTS, targets within the central nervous system (CNS) may offer exciting opportunities...
  22. ncbi alpha1-adrenoceptors and bladder function
    K Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Eur Urol 36:96-102. 1999
    ..To discuss the role of alpha-adrenoceptors (alpha-ARs) in the control of lower urinary tract function with special emphasis on their importance in the pathologically changed bladder...
  23. ncbi New directions for erectile dysfunction therapies
    K E Andersson
    Department of Clinical Pharmacology, Lund University Hospital, S 22185, Lund, Sweden
    Int J Impot Res 14:S82-92. 2002
    ..The final direction is prevention strategies. Strategies to prevent cavernosal degeneration and/or to restore cavernosal function will be one of the most exciting challenges for future research...
  24. ncbi Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
    Claudius Fullhase
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC, USA
    BJU Int 106:287-93. 2010
    ....
  25. ncbi Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction
    Christian Gratzke
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden
    J Urol 185:731-6. 2011
    ....
  26. ncbi Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice
    Annette Schroder
    Department of Clinical Pharmacology, Lund University Hospital, 221 85 Lund, Sweden
    J Urol 172:1166-70. 2004
    ....
  27. ncbi Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction
    Annette Schroder
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Sweden
    BJU Int 98:637-42. 2006
    ..g. hypertrophy and loss of contractile function, as vitamin D3 and BXL-628 inhibit prostate and bladder cell growth in vitro, and there are receptors for vitamin D in rat and human bladder...
  28. ncbi Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects
    Viktoria Werkström
    Department of Clinical and Experimental Pharmacology, Institute for Laboratory Medicine, Lund University Hospital, Lund, Sweden
    BJU Int 98:414-23. 2006
    ....
  29. ncbi Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering
    Shantaram Bharadwaj
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27101, USA
    Tissue Eng Part A 17:2123-32. 2011
    ....
  30. ncbi Protective effect of an oral endothelin converting enzyme inhibitor on rat detrusor function after outlet obstruction
    Annette Schroder
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    J Urol 172:1171-4. 2004
    ..We investigated the effect of an orally administered ECE inhibitor by cystometry in conscious rats with and without BOO...
  31. ncbi Impact of partial urethral obstruction on bladder function: time-dependent changes and functional correlates of altered expression of Ca²⁺ signaling regulators
    David Burmeister
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Am J Physiol Renal Physiol 302:F1517-28. 2012
    ..These data extend prior work to suggest that molecular profiling of key regulatory molecules during the progression of PUO-mediated bladder dysfunction may shed new light on potential biomarkers and/or therapeutic targets...
  32. ncbi Smooth-muscle-specific gene transfer with the human maxi-k channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys
    George J Christ
    Wake Forest Institute for Regenerative Medicine, Wake Forest University Primate Center, Department of Comparative Medicine, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Eur Urol 56:1055-66. 2009
    ..Despite the advent of effective oral therapies for erectile dysfunction (ED), many patients are not successfully treated, and side effects have been documented...
  33. ncbi Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue
    Dawn M Delo
    Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    BJU Int 102:878-84. 2008
    ....
  34. ncbi Bladder activation: afferent mechanisms
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Urology 59:43-50. 2002
    ..However, it is most likely that a cascade of inhibitory and stimulatory transmitters/mediators, as well as ATP, are involved in the transduction mechanisms underlying the activation of afferent fibers during bladder filling...
  35. ncbi Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats
    Petter Hedlund
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden
    J Urol 178:326-31. 2007
    ..We tested the hypothesis that, if tolterodine exerts some of its effects on afferent nerves, the functional elimination of C-fiber afferents should affect the actions of the drug on urodynamic parameters...
  36. ncbi Transmitters contributing to the voiding contraction in female rats
    Tomi Streng
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden
    BJU Int 94:910-4. 2004
    ....
  37. ncbi Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction
    Claudius Fullhase
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, North Carolina 27157, USA
    J Urol 184:783-9. 2010
    ....
  38. ncbi Alterations in bladder function associated with urothelial defects in uroplakin II and IIIa knockout mice
    Tamer AbouShwareb
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Neurourol Urodyn 28:1028-33. 2009
    ..The effects of deleting genes encoding uroplakins II (UPII) and III (UPIIIa) on mouse bladder physiology/dysfunction were studied in male and female wild type and knockout (KO) mice...
  39. ncbi Urine derived cells are a potential source for urological tissue reconstruction
    Yuanyuan Zhang
    Institute for Regenerative Medicine, School of Medicine, Wake Forest University, Winston Salem, North Carolina 27157, USA
    J Urol 180:2226-33. 2008
    ..We determined whether the cells present in urine have characteristics of normal bladder cells and investigated their potential uses for urological reconstructive procedures...
  40. ncbi Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity
    Christian Gratzke
    Department of Clinical Chemistry and Pharmacology, Lund University Hospital, S 22185 Lund, Sweden
    Eur Urol 57:342-8. 2010
    ..However, no information is available on the distribution of CB-receptors or effects by anandamide in CC from primates or humans...
  41. ncbi Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction
    Claudius Fullhase
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC, USA
    Neurourol Urodyn 30:1382-7. 2011
    ....
  42. ncbi Effects of long-term dietary soy treatment on female urethral morphology and function in ovariectomized nonhuman primates
    Christian Gratzke
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, North Carolina 27157, USA
    J Urol 180:2247-53. 2008
    ..Whether such effects can be achieved by soy based phytoestrogen diets is unclear. We studied the effects of chronic phytoestrogen treatment on the structural and functional properties of the urethra in ovariectomized monkeys...
  43. ncbi Impaired bladder function in aging male rats
    Weixin Zhao
    Wake Forest Institute for Regenerative Medicine, Winston Salem, North Carolina, USA
    J Urol 184:378-85. 2010
    ..Some confounding variables can be avoided by studying age related changes in an animal model. We evaluated the impact of age on bladder function in vivo and in vitro, and characterized the corresponding morphological changes...
  44. ncbi Bladder overactivity in mice after 1 week of outlet obstruction. Mainly afferent dysfunction?
    Annette Schroder
    Department of Clinical Pharmacology, Lund University Hospital, 221 85 Lund, Sweden
    J Urol 170:1017-21. 2003
    ..We investigated the correlation between different micturition patterns, post-void residual urine, bladder capacity, bladder weight and in vitro contractility in a conscious mouse model of BOO...
  45. ncbi Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats
    Christian Gratzke
    Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden
    Eur Urol 57:1093-100. 2010
    ..Cannabinoid (CB) receptors may be involved in the control of bladder function; the role of CB receptor subtypes in micturition has not been established...
  46. ncbi Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder
    Viktoria Werkström
    Department of Clinical and Experimental Pharmacology, Institute for Laboratory Medicine, Lund University Hospital, Lund, Sweden
    BJU Int 104:1740-5. 2009
    ....
  47. ncbi Microarray analysis of exstrophic human bladder smooth muscle
    Jason Hipp
    Department of Urology, Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC 27157, USA
    BJU Int 101:100-5. 2008
    ....
  48. ncbi Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Neurourol Urodyn 26:928-33. 2007
    ..Information for the review was obtained from searches of the PubMed database, and from the authors' files...
  49. ncbi Rodent models for urodynamic investigation
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC, USA
    Neurourol Urodyn 30:636-46. 2011
    ..The present review discusses the principles of urodynamics in rodents, techniques, and terminology, as well as some commonly used disease models, and their translational value...
  50. ncbi Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies
    Lysanne Campeau
    Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Curr Urol Rep 12:396-403. 2011
    ..This review presents the most recent studies and evidence on the pathophysiological mechanisms of PD-related voiding dysfunction and its available therapies...
  51. ncbi Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells
    Christian Gratzke
    Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, USA
    Eur Urol 57:902-10. 2010
    ..Ion channel transient receptor potential A1 (TRPA1) and cannabinoid (CB) receptors are involved in mechanoafferent signaling from the bladder and the urethra...
  52. ncbi Development of bladder dysfunction in a rat model of dopaminergic brain lesion
    Roberto Soler
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, North Carolina 27157, USA
    Neurourol Urodyn 30:188-93. 2011
    ..We evaluated the temporal development of bladder dysfunction in rat PD model where urodynamic changes were induced by unilateral injection of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB)...
  53. ncbi Bladder dysfunction in a new mutant mouse model with increased superoxide--lack of nitric oxide?
    Roberto Soler
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, North Carolina, USA
    J Urol 183:780-5. 2010
    ..Mice with mutation in the Immp2l gene have high superoxide ion levels and a consequent decrease in the bioavailable amount of nitric oxide. We studied bladder function in this mouse model...
  54. ncbi Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats--effects of bladder outlet obstruction and intravesical PGE2
    Tack Lee
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden
    Neurourol Urodyn 27:88-95. 2008
    ..In addition, IAP and IVP were recorded in rats with experimental detrusor overactivity (DO)...
  55. ncbi Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract
    George J Christ
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Neurourol Urodyn 26:948-54. 2007
    ..Rho-kinase inhibitors thus appear to represent a potentially attractive therapeutic possibility for the treatment of LUTS...
  56. ncbi ATP- and adenosine-induced relaxation of the smooth muscle of the pig urethra
    Viktoria Werkström
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden
    BJU Int 96:1386-91. 2005
    ....
  57. ncbi Estrogen receptor subtypes and afferent signaling in the bladder
    Annette Schroder
    Department of Clinical Pharmacology, Lund University Hospital, 221 85 Lund, Sweden
    J Urol 170:1013-6. 2003
    ..In addition to the well-known estrogen receptor (ER)alpha, recently the ER subtype ERbeta was discovered. We investigated potential changes in bladder function in mice lacking either 1 or both receptor subtypes compared with WT mice...
  58. ncbi Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease
    Roberto Soler
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, North Carolina, USA
    J Urol 187:1491-7. 2012
    ..We evaluated the effect of human amniotic fluid stem cells and bone marrow derived mesenchymal stem cells (ALLCELLS, Emeryville, California) on bladder dysfunction in a rat model of Parkinson disease...
  59. ncbi Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction
    Tack Lee
    Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden
    J Urol 177:1562-7. 2007
    ..We investigated if the new EP(1) receptor antagonist PF-2907617-02 would influence the regulation of normal micturition in rats, and if it affects bladder function in animals with partial bladder outlet obstruction...
  60. ncbi Microarray analysis of bladder smooth muscle from patients with myelomeningocele
    Jennifer A Hipp
    Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC 27157, USA
    BJU Int 102:741-6. 2008
    ....
  61. ncbi Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder
    Christian Gratzke
    Wake Forest Institute for Regenerative Medicine, Winston Salem, North Carolina, USA
    J Urol 181:1939-48. 2009
    ..We investigated the distribution of cannabinoid receptor subtypes 1 and 2 in the detrusor of different species and studied the effects of cannabinoid receptor 1 and 2 agonists on bladder function...
  62. ncbi Transient receptor potential A1 (TRPA1) activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region
    Christian Gratzke
    Department of Clinical Chemistry and Pharmacology, Lund University Hospital, Lund, Sweden
    Eur Urol 55:696-704. 2009
    ..A role for the transient receptor potential (TRP) A1 ion channel in rat lower urinary tract (LUT) sensation and disease has been proposed, but in the human LUT no information on TRPA1 activity is available...
  63. ncbi Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Br J Clin Pharmacol 72:186-96. 2011
    ..Differences between drugs cannot be excluded, but risk assessments based on available evidence are not possible...
  64. ncbi Signal transduction pathways of muscarinic receptor mediated activation in the newborn and adult mouse urinary bladder
    Mari Ekman
    Department of Experimental Medical Science, Lund University, Lund, Sweden
    BJU Int 103:90-7. 2009
    ....
  65. ncbi Metrics for evaluation of age-related changes in erectile capacity in a rodent model
    Weixin Zhao
    Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Medical Center Blvd, Winston Salem, NC 27157, USA
    J Sex Med 6:1885-92. 2009
    ..The observed penile erection can be characterized by the change in ICP and the ratio of ICP over blood pressure (BP; systemic blood pressure)...
  66. ncbi The role of the rhabdosphincter in female rat voiding
    Tomi Streng
    Institute of Biomedicine, Department of Anatomy, University of Turku, Turku, Finland
    BJU Int 94:138-42. 2004
    ....
  67. ncbi Regenerative pharmacology: the future is now
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Mol Interv 7:79-86. 2007
    ....
  68. ncbi A canine model of irreversible urethral sphincter insufficiency
    Daniel Eberli
    Wake Forest Institute for Regenerative Medicine, Medical Center Boulevard, Winston Salem, NC 27514 1094, USA
    BJU Int 103:248-53. 2009
    ....
  69. ncbi Are female lower urinary tract symptoms alleviated by alpha-adrenoreceptor antagonists?
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Nat Clin Pract Urol 5:586-7. 2008
    ..Without urodynamic characterization, it cannot be established whether patients in the study were obstructed, or whether the effect of terazosin was related to a decrease in bladder outflow resistance...
  70. ncbi Voiding pattern analysis as a surrogate for cystometric evaluation in uroplakin II knockout mice
    Steve J Hodges
    Wake Forest Institute of Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    J Urol 179:2046-51. 2008
    ..We developed a simple surrogate measure of bladder function using ultraviolet visualization of urinary voiding patterns in a uroplakin II knockout mouse animal model...
  71. ncbi Treatment of the overactive bladder: possible central nervous system drug targets
    Karl Erik Andersson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    Urology 59:18-24. 2002
    ..However, a selective action on the lower urinary tract may be difficult to obtain...
  72. ncbi Urothelial effects of oral agents for overactive bladder
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Curr Urol Rep 9:459-64. 2008
    ..This has not yet been demonstrated to imply superior clinical efficacy. Nevertheless, mucosal afferent signaling pathways are therapeutically interesting targets that should be further explored...
  73. ncbi Receptor-induced phasic activity of newborn mouse bladders is inhibited by protein kinase C and involves T-type Ca2+ channels
    Mari Ekman
    Department of Experimental Medical Science, Lund University, Lund, Sweden
    BJU Int 104:690-7. 2009
    ..To investigate the mechanisms involved in the phasic contractile activity after muscarinic receptor activation of newborn urinary bladders and to compare neonatal and adult bladders...
  74. ncbi Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction
    Rikard Pehrson
    Department of Clinical Pharmacology, Institute for Laboratory Medicine, Lund University Hospital, S-221 85 Lund, Sweden
    Eur Urol 44:495-9. 2003
    ..CONCLUSION: Tramadol normalised detrusor overactivity in MCA-occluded rats. The drug might have a treatment potential in patients with detrusor overactivity after stroke...
  75. ncbi Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns
    A Rembratt
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    BJU Int 91:642-6. 2003
    ..To investigate the short-term safety of desmopressin in elderly patients with nocturia, with special focus on the risk of hyponatraemia, and to assess the short-term effects on urine output, sleep and voiding patterns...
  76. ncbi Pharmacotherapy of the overactive bladder
    Karl Erik Andersson
    Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, United States
    Discov Med 8:118-24. 2009
    ..Which of these therapeutic principles will be developed to become clinically useful treatments remain to be established...
  77. ncbi Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina 27157, USA
    Curr Opin Urol 19:380-94. 2009
    ..Individual drugs are not discussed in detail; particular consideration is given to therapeutic aspects of the management of the elderly patient...
  78. ncbi A mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in mice
    Baisong Lu
    Institute for Regenerative Medicine, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    Biol Reprod 78:601-10. 2008
    ..The results provide a novel link between mitochondrial dysfunction and infertility and suggest that superoxide ion targeting agents may prove useful for treating infertility in a subpopulation of infertile patients...
  79. ncbi Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations
    Karl Erik Andersson
    Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA
    BJU Int 100:1007-14. 2007
    ..This is without doubt the most detailed and the most reader-friendly paper on this subject, and I am sure that it will help urologists to assist in further educating their patients when prescribing these compounds...
  80. ncbi Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder
    Karl Erik Andersson
    Wake Forest University, Winston Salem, NC, USA
    BJU Int 106:268-74. 2010
    ....
  81. ncbi Nocturia and associated morbidity in a community-dwelling elderly population
    A Rembratt
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    BJU Int 92:726-30. 2003
    ..The number of nocturnal voids was highly correlated with urge and incontinence...
  82. ncbi Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly
    A Rembratt
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    BJU Int 91:45-50. 2003
    ..To evaluate differences between elderly people with and without nocturia (waking up in the night to void) in terms of voiding habits, urine production and voided volumes...
  83. ncbi Expression of nitric oxide synthase in bladder smooth muscle cells: regulation by cytokines and L-arginine
    R K Johansson
    Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
    J Urol 168:2280-5. 2002
    ..CONCLUSIONS: NOS was not detected in unstimulated bladder smooth muscle cells. However, bladder smooth muscle has the potential to express iNOS when exposed to cytokines known to be produced during urinary tract infection...
  84. ncbi Overview consensus statement
    David R Staskin
    Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA
    Urology 60:1-6. 2002